Collectively, our data indicate that restoring p53 function via SGT-53 is able to boost anti-tumor immunity to enhance anti-PD1 immunotherapy by sensitizing tumors while reducing immune-related adverse events. The gene discussed is PDCD1; the disease is neoplasm.